Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Dizziness and poor sleep need context
Dizziness on standing and poor sleep need clinical context, not a new peptide stack or a forum-based treatment plan.
GLP-1 Mental Health Data in Teens
A small chart review found no short-term increase in suicidality screens among adolescents with obesity using liraglutide or semaglutide.
What a tirzepatide COA cannot verify
A COA may describe a tested sample, but it cannot replace FDA approval, licensed pharmacy dispensing, or individual clinical assessment.
Tirzepatide in pasireotide hyperglycemia
A new case report found improved glucose measures after tirzepatide in one patient with pasireotide-related hyperglycemia. Here is what it can and cannot show.
Foundayo's $98 million launch quarter
Lilly reported $98 million in Q2 revenue for oral GLP-1 Foundayo. The filing shows an early launch, not proof that the medicine disappointed.
GLP-1 Drugs and Skin Disease Evidence
A 2026 review finds the strongest GLP-1 skin evidence in psoriasis, while most other dermatology uses remain observational.
Do GLP-1 Drugs Affect Muscle and Bone?
A 2026 meta-analysis found a low-certainty lean-mass signal with GLP-1 drugs, but no adjusted effect on bone or joint outcomes.
How GLP-1 Analogs Are Engineered
A 2026 review explains how GLP-1 analogs use sequence changes, peptide shape and lipidation to resist breakdown and last longer.
Knee Surgery: Semaglutide vs Tirzepatide
A matched US study found similar short-term knee-replacement outcomes in people with diabetes prescribed semaglutide or tirzepatide.
Semaglutide pregnancy case series
A 2026 case series reported outcomes after first-trimester semaglutide exposure in 16 pregnancies. The result is useful but cannot establish safety.
GLP-1 Drugs and Anesthesia Safety
A 2026 study compared anesthesia outcomes for lipoabdominoplasty patients taking semaglutide or tirzepatide against those who were not.
Do your genes affect incretin response?
Common variants in GLP1R and GIPR may shift weight loss outcomes and tolerability on semaglutide and tirzepatide, a 2026 review finds.